Chronic obstructive pulmonary disease (COPD), which includes emphysema and chronic bronchitis, affects more than 30 million ...
Inhalers for COPD provide steroids, bronchodilators, or combination drugs. The three types differ in the mechanism by which the medication is inhaled and have different instructions for use. If you ...
RIDGEFIELD, Conn., April 13 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced that the U.S. Food and Drug Administration (FDA) has determined that the "essential use" ...
October 7, 2011 — The US Food and Drug Administration (FDA) has granted approval for an ipratropium bromide and albuterol sulfate inhalation spray (Combivent Respimat Inhalation Spray, Boehringer ...
U.S. regulators have stamped an approval on a new inhaler that reduces the required inhalations per dose for Boehringer Ingelheim's treatment for chronic obstructive pulmonary disease (COPD), the ...
The U.S. Food and Drug Administration announced seven metered-dose inhalers (MDIs) used to treat asthma and chronic obstructive pulmonary disease (COPD) will be gradually removed from the U.S.
Boehringer Ingelheim Pharmaceuticals, Inc. announced that the US Food and Drug Administration (US FDA) has approved Combivent Respimat, a new, propellant-free inhaler product that uses a slow-moving ...
A new analysis that compares two common inhalers for patients suffering from chronic obstructive pulmonary disease (COPD) finds that one reduces respiratory-related hospitalizations and respiratory ...
COMBIVENT RESPIMAT (ipratropium bromide and albuterol) propellant-free MDI by Boehringer Ingelheim Boehringer Ingelheim announced that Combivent Respimat (ipratropium bromide and albuterol) inhalation ...
A new analysis that compares two common inhalers for patients suffering from chronic obstructive pulmonary disease (COPD) finds that one reduces respiratory-related hospitalizations and respiratory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results